Journal: Frontiers in Pharmacology

Article Title: BMP10 accelerated spinal astrocytic activation in neuropathic pain via ALK2/smad1/5/8 signaling

doi: 10.3389/fphar.2024.1426121

Figure Lengend Snippet: Graphical representation of the experimental design. Experiment 1: Changes in pain sensitization and expressions of BMP10, ALK2, Smad1/5/8, phosphorylated Smad1/5/8, and GFAP after SNI in mice. Experiment 2: The effects of BMP10 siRNA on SNI-induced pain hypersensitivity and astrocytic activation. Experiment 3: The involvements of ALK2 in BMP10-induced pain hypersensitivity and astrocytic activation. Experiment 4: The effects of Smad1 siRNA on BMP10-induced pain hypersensitivity and astrocytic activation.

Article Snippet: The membranes were incubated with appropriate antibodies, including mouse anti-GFAP antibody (1:1,000, ab279289, Abcam), mouse anti-BMP10 antibody (1:1,000, 462732, Novus Biologicals, CO, United States), rabbit anti-ALK2 antibody (1:100, PA5-114818, Thermo Fisher Scientific, MA, United States), rabbit anti-phospho-Smad1/5/8 (1:1,000, AB3848-I, Sigma Aldrich, Germany), rabbit anti-Smad1/5/8 (1:1,000, NB100-56656, Novus Biologicals, CO, United States) and mouse anti-β-actin (1:1,000, AF2815, Beyotime Biotechnology , Shanghai, China) overnight at 4°C.

Techniques: Activation Assay

Journal: Frontiers in Pharmacology

Article Title: BMP10 accelerated spinal astrocytic activation in neuropathic pain via ALK2/smad1/5/8 signaling

doi: 10.3389/fphar.2024.1426121

Figure Lengend Snippet: Expression levels of ALK2, Samd1/5/8, and p-Smad1/5/8 in mouse ipsilateral spinal dorsal horn after SNI. (A–C) Western blot analysis showed the expression levels of ALK2, Samd1/5/8, and p-Smad1/5/8 in the ipsilateral (above) and contralateral (below) spinal dorsal horn of sham and SNI mice; (D) Double immunofluorescence staining showed the coexpression of ALK2 (red) with GFAP, Iba-1 and NeuN (green) in the ipsilateral spinal dorsal horn of SNI mice on postoperative Day 14 (scale bar = 50 μm/25 μm). Data are presented as mean and SEM; sham mice versus SNI mice on postoperative Days 7 and 14, *** p < 0.001 (n = 6).

Article Snippet: The membranes were incubated with appropriate antibodies, including mouse anti-GFAP antibody (1:1,000, ab279289, Abcam), mouse anti-BMP10 antibody (1:1,000, 462732, Novus Biologicals, CO, United States), rabbit anti-ALK2 antibody (1:100, PA5-114818, Thermo Fisher Scientific, MA, United States), rabbit anti-phospho-Smad1/5/8 (1:1,000, AB3848-I, Sigma Aldrich, Germany), rabbit anti-Smad1/5/8 (1:1,000, NB100-56656, Novus Biologicals, CO, United States) and mouse anti-β-actin (1:1,000, AF2815, Beyotime Biotechnology , Shanghai, China) overnight at 4°C.

Techniques: Expressing, Western Blot, Double Immunofluorescence Staining

Journal: Frontiers in Pharmacology

Article Title: BMP10 accelerated spinal astrocytic activation in neuropathic pain via ALK2/smad1/5/8 signaling

doi: 10.3389/fphar.2024.1426121

Figure Lengend Snippet: ALK2 was involved in BMP10-induced pain hypersensitivity and astrocytic activation. (A, B) The time course of PWT and TWL in normal mice after intrathecal delivery of BMP10 peptide and reagents; Data are presented as mean and SEM, Vehicle group versus BMP10 group * p < 0.05, ** p < 0.01, *** p < 0.001; BMP10+ALK2-IN-2 group versus BMP group # p < 0.05, ## p < 0.01, ### p < 0.001 (n = 12); (C) Representative movement traces in OFT tests of mice after intrathecal delivery of BMP10 peptide and reagents; (D–F) Time in center zone, average speed and total distance of mice in open field after intrathecal delivery of BMP10 peptide and reagents; (G, H) immunofluorescence staining showed the expression of GFAP in the spinal dorsal horn after intrathecal delivery of BMP10 peptide and reagents (scale bar = 200/50 μm); (I) Western blot showed the expression of GFAP in the spinal cord after intrathecal delivery of BMP10 peptide and reagents; Data are presented as mean and SEM, Vehicle group versus BMP10 group * p < 0.05, ** p < 0.01, *** p < 0.001; BMP10+ ALK2-IN-2 group versus BMP group # p < 0.05, ## p < 0.01, ### p < 0.001 (n = 6).

Article Snippet: The membranes were incubated with appropriate antibodies, including mouse anti-GFAP antibody (1:1,000, ab279289, Abcam), mouse anti-BMP10 antibody (1:1,000, 462732, Novus Biologicals, CO, United States), rabbit anti-ALK2 antibody (1:100, PA5-114818, Thermo Fisher Scientific, MA, United States), rabbit anti-phospho-Smad1/5/8 (1:1,000, AB3848-I, Sigma Aldrich, Germany), rabbit anti-Smad1/5/8 (1:1,000, NB100-56656, Novus Biologicals, CO, United States) and mouse anti-β-actin (1:1,000, AF2815, Beyotime Biotechnology , Shanghai, China) overnight at 4°C.

Techniques: Activation Assay, Immunofluorescence, Staining, Expressing, Western Blot

Journal: Biology

Article Title: BMP-2-Driven Osteogenesis: A Comparative Analysis of Porcine BMSCs and ASCs and the Role of TGF-β and FGF Signaling.

doi: 10.3390/biology14060610

Figure Lengend Snippet: Figure 6. Receptor expressions of ALK2, ALK4, ALK6, ALK5, ALK7, BMPR-II in pASC. Grouped representation of the respective receptor expression in the course of osteogenic differentiation (OM +/−BMP-2). From day 19, there is a significant induction of ALK 2, ALK 6, and ALK 5 with the addition of BMP-2. BMPR-II expression in the OM group decreased in OM and tended to stay increased under BMP-2 supplementation from day 19, but was not considered significant (* p ≤0.05, ** p ≤0.01; n = 6, BMP-2 450 ng/mL).

Article Snippet: The respective conjugated antibodies were used for the expressions of ALK3 (Cat. No.: AF436), ALK 5 (Cat. No.: FAB5871), ALK6 (Cat. No.: FAB5051A), TGF-β2-RII (Cat. No.: FAB532P), ALK7 (Cat. No.: FAB77491A), ALK2 (Cat. No.: AF637), ALK4 (Cat. No.: MAB2221), and BMPR-II (Cat. No.: AF811) (by R&D Systems, Minneapolis, MN, USA), and the pASCs and pBMSCs were compared for their expressions of the specific surface antigens CD45 (Cat. No.: MCA1568GA, BioRad, Hercules, CA, USA), HLA-DR (human leukocyte antigen–antigen D-related surface molecule) (Cat. No.: MCA2314F, Bio-Rad, Hercules, CA, USA), CD29 (Cat. No.: 561,496, BD Pharmingen, Franklin Lakes, NJ, USA), CD79alpha (Bio-Rad, Cat. No.: MCA2538GA), CD14 (Cat. No.: MCA1568GA, Bio-Rad, Hercules, CA, USA), CD31 (Cat. No.: AF3387, R&D Systems, Minneapolis, MN, USA), CD105 (Cat. No.: NB110-58718APC, Novus Biologicals, Minneapolis, MN, USA), CD26 (, Cat. No.: NB600-552APC, Novus Biologicals, Minneapolis, MN, USA), CD73 (, Cat. No.: AF4488, R&D Systems, Minneapolis, MN, USA), CD90 (Cat. No.: 559,869, BD Pharmingen, Franklin Lakes, NJ, USA), CD34 (Cat. No.: 81289, abcam, Cambridge, UK), and CD44 (Cat. No.: 5531, BD Pharmingen, Franklin Lakes, NJ, USA).

Techniques: Expressing